Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

By afschroeder • May 16, 2026

Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani N, Rueda MJ, Cardoso A, Genovese MC, Armstrong AW, Strober B. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol. 2026 May 15:e261753. doi: 10.1001/jamadermatol.2026.1753. Epub ahead of print. PMID: 42139049; PMCID: PMC13179568.

Tags: Dermatology, Publications

Related Posts

A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel

Shah M, DeBusk L, Bohman MH, Rosenberg A, Burshtein J, Zakria D, Armstrong A, Boh E, Gottlieb AB, Khattri S, Litchman G, Merola J, Murina[...]

The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains

Zakria D, Shah M, Rosenberg A, Burshtein J, DeBusk L, Altman DA, Armstrong AW, Gottlieb AB, Han G, Khattri S, Shaigany S, Weinberg JM, Lebwohl[...]

Vitiligo in the United States: A 10-year study of patient characteristics, comorbidities, and treatment patterns

Huang MY, Smart K, Lee K, Kingston P, Yee D, Peterson H, Korouri E, Armstrong AW. Vitiligo in the United States: A 10-year study of[...]